- Home
- VTOL vs CGEM Comparison
VTOL vs CGEM Comparison
Compare VTOL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTOL | CGEM |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | 109 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VTOL | CGEM |
|---|---|---|
| Price | $41.66 | $20.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $58.00 | $30.13 |
| AVG Volume (30 Days) | 233.8K | ★ 750.3K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 34.58 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,490,512,000.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $5.59 | $5.20 |
| P/E Ratio | $36.32 | ★ N/A |
| Revenue Growth | ★ 5.30 | N/A |
| 52 Week Low | $35.03 | $5.68 |
| 52 Week High | $50.38 | $23.19 |
Technical Indicators
Market Signals| Indicator | VTOL | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 49.46 |
| Support Level | $41.28 | $11.87 |
| Resistance Level | $47.03 | $23.19 |
| Average True Range (ATR) | 1.40 | 0.96 |
| MACD | -0.29 | -0.26 |
| Stochastic Oscillator | 20.65 | 51.40 |
Price Performance
Historical ComparisonAbout VTOL Bristow Group Inc.
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers are in the UK, Norway, the USA, Nigeria, and Others. The offshore energy customers use services to transport personnel to, from and between offshore energy installations. The majority of revenue is generated from Offshore Energy Services.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.